Cardio-renal outcomes with SGLT2 inhibitors in CKD patients with HFpEF
Official title: Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients
Run by Grigore T. Popa University of Medicine and Pharmacy · NCT07237451 · Data updated 2026-11-12
This project will try to see if people with stage 3–4 CKD and HFpEF who take SGLT2 inhibitors have better heart and kidney outcomes than similar patients who do not.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Grigore T. Popa University of Medicine and Pharmacy Academic / other |
| Locations | 1 site (Iași) |
| Status | Recruiting |
| Started | January 8, 2025 |
| Main results expected | March 1, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | November 19, 2025 |
| Trial ID | NCT07237451 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with stage 3–4 CKD (eGFR 15–60 mL/min/1.73 m2) and HFpEF (EF >40%), including both diabetic and non-diabetic patients, who are either taking an SGLT2 inhibitor or are matched nonusers.
✕Probably not a fit
People with end-stage kidney disease (eGFR <15 mL/min/1.73 m2) on dialysis, active malignancy, decompensated cirrhosis, congenital heart disease, recent significant coronary artery disease, implanted cardiac devices, pregnancy, or active infection are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational cohort will follow adults with stage 3–4 chronic kidney disease and heart failure with preserved ejection fraction who are matched by age, sex, and CKD stage and either taking or not taking SGLT2 inhibitors. Investigators will record clinical events including major adverse cardiovascular events and mortality and perform vascular and cardiac function testing such as flow-mediated dilation, carotid-femoral pulse wave velocity, intima-media thickness, and echocardiography. Participants will also undergo NMR metabolomics and a panel of novel biomarkers and uremic toxin mapping to explore biological mechanisms linking SGLT2 use to outcomes. Because therapy is not assigned, the design focuses on real-world associations and mechanistic insights rather than randomized causal inference.
Why it matters
Potential benefit: If successful, the findings could help clarify whether SGLT2 inhibitors improve cardiovascular and renal outcomes and identify biomarkers that predict benefit in CKD patients with HFpEF.
How similar studies have gone: Large randomized trials have already shown cardiovascular and renal benefits of SGLT2 inhibitors in broader heart failure and CKD populations, but this observational cohort applies similar drugs specifically to HFpEF with detailed vascular and metabolomic profiling, making the mechanistic approach relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age\>18 years; * ejection fraction \> 40; * patients with CKD stage 3-4 (eGFR between 15-60 mL/min/1.73m2), with iSGLT2 recommendation, diabetic and non-diabetic; * age, sex and CKD stage 3 and 4 matched patients without iSGLT2 administration. Exclusion Criteria: * eGFR\< 15 mL/min/1.73m2 or patients undergoing dialysis; * presence of congenital heart disease, decompensated cirrhosis, pregnancy and active malignancies; * coronary artery disease (including those with a history of acute coronary syndrome, angina pectoris, or prior coronary angiography or CT angiography demonstrating significant coronary artery lesions); * cardiac medical devices, namely metallic joint prostheses, cardiac stent or pacemakers; * active systemic infections (due to interference with biomarkers that can give false rise values).
Where it's running
-
Dr. C.I. Parhon Hospital in Iasi
Iași, Romania Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Continuous temperature monitoring of the feet with connected insoles and a smartphone app in adults with diabetes at high risk
This trial tests whether the Solsius SelfCare system can reliably flag pre-ulcer foot changes in adults with diabetes by detecting temperature differences between feet for at least two consecutive days.
-
RIGHTEST iFree 2 CGM system for better diabetes control in adults on insulin
A real-time CGM system is tested to see if it improves blood sugar control for adults with type 1 or type 2 diabetes on insulin, compared with finger-stick monitoring.
-
Using Risk Thanks to Predictions to Find CKD Risk and Improve Testing
We’re testing whether targeted provider and patient communications can help people at high risk for chronic kidney disease get the recommended kidney tests.
-
Walnuts and a Mediterranean-style diet to protect kidney and heart health
This study tests whether adding 30 g of raw walnuts daily to a Mediterranean-style diet helps kidney function and heart risk markers in adults with chronic kidney disease.
-
Benefits of Retained Insulin for Good Health in Diabetes
This study tests whether preserving or restoring a person’s own insulin production can improve quality of life and blood sugar control for people who need insulin to manage diabetes.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.